Change search
ReferencesLink to record
Permanent link

Direct link
Association between TERT promoter polymorphisms and acute myeloid leukemia risk and prognosis
Linköping University, Department of Clinical and Experimental Medicine. Linköping University, Faculty of Medicine and Health Sciences.
Linköping University, Department of Clinical and Experimental Medicine, Division of Cell Biology. Linköping University, Faculty of Medicine and Health Sciences. Region Östergötland, Center for Surgery, Orthopaedics and Cancer Treatment, Department of Haematology.
Linköping University, Department of Medical and Health Sciences, Division of Drug Research. Linköping University, Faculty of Medicine and Health Sciences.ORCID iD: 0000-0003-4450-0333
Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden.
Show others and affiliations
2015 (English)In: OncoTarget, ISSN 1949-2553, E-ISSN 1949-2553, Vol. 6, no 28, 25109-25120 p.Article in journal (Refereed) Published
Abstract [en]

Telomerase reverse transcriptase gene (TERT) promoter mutations are identified in many malignancies but not in hematological malignancies. Here we analyzed TERT and protection of telomeres 1 gene (POT1) mutations, and four different TERT SNVs in 226 acute myeloid leukemia (AML) patients and 806 healthy individuals in a case referent design, where also overall survival was assessed. A significant association for increased risk of AML was found for TERT SNVs, rs2853669 (OR = 2.45, p = 0.00015) and rs2736100 (OR = 1.5, p = 0.03). The overall survival for patients with CC genotype of rs2853669 was significantly shorter compared to those with TT or TC genotypes (p = 0.036 and 0.029 respectively). The influence of TERT rs2853669 CC on survival was confirmed in multivariable Cox regression analysis as an independent risk biomarker in addition to high risk group, higher age and treatment. No hot spot TERT promoter mutations at -228Cgreater thanT or -250Cgreater thanT or POT1 mutations could be identified in this AML cohort. We show that rs2853669 CC may be a risk factor for the development of AML that may also be used as a prognostic marker to identify high risk normal karyotype -AML (NK-AML) patients, for treatment guidance.

Place, publisher, year, edition, pages
Albany, NY, United States: Impact Journals LLC , 2015. Vol. 6, no 28, 25109-25120 p.
Keyword [en]
TERT; SNV; AML; prognostic markers
National Category
Clinical Medicine
URN: urn:nbn:se:liu:diva-122667DOI: 10.18632/oncotarget.4668ISI: 000363160100047OAI: diva2:871672

Funding Agencies|Swedish Research Council; Swedish Cancer Society; County Council of Ostergotland; AFA Insurance; FORSS

Available from: 2015-11-16 Created: 2015-11-13 Last updated: 2015-12-10Bibliographically approved

Open Access in DiVA

fulltext(1642 kB)31 downloads
File information
File name FULLTEXT01.pdfFile size 1642 kBChecksum SHA-512
Type fulltextMimetype application/pdf

Other links

Publisher's full text

Search in DiVA

By author/editor
Mosrati, Mohamed AliWillander, KerstinJakobsen Falk, IngridLotfi, KouroshSöderkvist, Peter
By organisation
Department of Clinical and Experimental MedicineFaculty of Medicine and Health SciencesDivision of Cell BiologyDepartment of HaematologyDivision of Drug ResearchDepartment of Clinical PharmacologyDepartment of Clinical Pathology and Clinical Genetics
In the same journal
Clinical Medicine

Search outside of DiVA

GoogleGoogle Scholar
Total: 31 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 149 hits
ReferencesLink to record
Permanent link

Direct link